Serum testosterone levels and testosterone 'bounce' phenomenon predict response to novel anti-androgen therapies in castration-resistant prostate cancer

被引：0
|
作者：
Tan, Y. G. [1 ]
Huang, H. H. [1 ]
Yuen, J. S. [1 ]
Tay, K. J. [1 ]
Tuan, J. K. [2 ]
Chen, K. [1 ]
机构：
[1] Singapore Gen Hosp, Dept Urol, Singapore, Singapore
[2] Singapore Gen Hosp, Dept Radiat Oncol, Singapore, Singapore
来源：
EUROPEAN UROLOGY | 2021年 / 79卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
P0858
引用
下载
收藏
页码：S1201 / S1201
页数：1
相关论文
共 50 条
  • [1] Serum testosterone levels and testosterone 'bounce' phenomenon predict response to novel anti-androgen therapies in castration-resistant prostate cancer
    Tan, Yu Guang
    Quek, Sheriff Z. H.
    Huang, Hong Hong
    Ho, Henry S. S.
    Yuen, John S. P.
    Tay, Kae Jack
    Tuan, Jeffrey K. L.
    Chen, Kenneth
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2021, 39 (12) : 829.e9 - 829.e17
  • [2] Testosterone levels in metastatic castration-resistant prostate cancer (mCRPC).
    von Klot, Christoph A. J.
    Boeker, Alena
    Herrmann, Thomas R. W.
    Kramer, Mario W.
    Kuczyk, Markus A.
    Merseburger, Axel S.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [3] Higher serum testosterone levels predict poor prognosis in castration-resistant prostate cancer patients treated with docetaxel
    Ando, Keisuke
    Sakamoto, Shinichi
    Takeshita, Nobushige
    Fujimoto, Ayumi
    Maimaiti, Maihulan
    Saito, Shinpei
    Sanjyon, Pae
    Imamura, Yusuke
    Sato, Nobuo
    Komiya, Akira
    Akakura, Koichiro
    Ichikawa, Tomohiko
    PROSTATE, 2020, 80 (03): : 247 - 255
  • [4] Effect of the novel anti-androgen ARN-509 on response and seizure in castration-resistant prostate cancer models
    Hager, J. H.
    Smith, N. D.
    Bischoff, E.
    Jung, M. E.
    Sawyers, C. L.
    Heyman, R. A.
    Rix, P. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [5] Targeting transcriptional addiction in anti-androgen refractory castration-resistant prostate cancer
    Rasool, Reyaz Ur
    Natesan, Ramakrishnan
    Deng, Qu
    Aras, Shweta
    Effron, Samuel Sander
    Velasquez, Erick Mitchell
    Posimo, Jessica M.
    Lal, Priti
    Brady, Donita C.
    Asangani, Irfan A.
    CANCER RESEARCH, 2020, 80 (16)
  • [6] Prognostic and Predictive Factors for Anti-androgen Withdrawal in Castration-resistant Prostate Cancer
    Murakami, Tomohiko
    Obata, Hirofumi
    Akitake, Naoko
    Shiota, Masaki
    Takeuchi, Ario
    Kashiwagi, Eiji
    Inokuchi, Junichi
    Tatsugami, Katsunori
    Eto, Masatoshi
    ANTICANCER RESEARCH, 2018, 38 (07) : 4115 - 4121
  • [7] The Role of Testosterone in the Treatment of Castration-Resistant Prostate Cancer
    Drazer, Michael W.
    Stadler, Walter M.
    CANCER JOURNAL, 2016, 22 (05): : 330 - 333
  • [8] Identification of favorable subgroups for alternative anti-androgen therapy in castration-resistant prostate cancer
    Suzuki, Kotaro
    Terakawa, Tomoaki
    Shigemura, Katsumi
    Furukawa, Junya
    Harada, Kenichi
    Hinata, Nobuyuki
    Nakano, Yuzo
    Fujisawa, Masato
    MOLECULAR AND CLINICAL ONCOLOGY, 2019, 11 (05) : 523 - 530
  • [9] Testosterone levels and androgen receptor copy number variations in castration-resistant prostate cancer treated with abiraterone or enzalutamide
    Lolli, Cristian
    De Lisi, Delia
    Conteduca, Vincenza
    Gurioli, Giorgia
    Scarpi, Emanuela
    Schepisi, Giuseppe
    Ravaglia, Giorgia
    Menna, Cecilia
    Farolfi, Alberto
    Altavilla, Amelia
    Burgio, Salvatore Luca
    Tonini, Giuseppe
    Santini, Daniele
    De Giorgi, Ugo
    PROSTATE, 2019, 79 (11): : 1211 - 1220
  • [10] Testosterone defining prognosis and predicting response in castration-resistant prostate cancer (CRPC)
    Gomez de Liano, A.
    Reig, O.
    Mellado, B.
    Martin, C.
    Sancho, G.
    Palou, J.
    Anguera, G.
    Arqueros, C.
    Condori, D.
    Maroto-Rey, P.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S702 - S702
12345